PHARMACOKINETICS SECTION.

12.3 Pharmacokinetics. The pharmacokinetics of valacyclovir and acyclovir after oral administration of valacyclovir hydrochloride have been investigated in 14 volunteer studies involving 283 adults and in studies involving 112 pediatric subjects from month to <12 years of age. Pharmacokinetics in Adults: Absorption and Bioavailability: After oral administration, valacyclovir hydrochloride is rapidly absorbed from the gastrointestinal tract and nearly completely converted to acyclovir and L-valine by first-pass intestinal and/or hepatic metabolism. The absolute bioavailability of acyclovir after administration of valacyclovir hydrochloride is 54.5% +- 9.1% as determined following 1 gram oral dose of valacyclovir hydrochloride and 350 mg intravenous acyclovir dose to 12 healthy volunteers. Acyclovir bioavailability from the administration of valacyclovir hydrochloride is not altered by administration with food(30 minutes after an 873 Kcal breakfast, which included 51 grams of fat). Acyclovir pharmacokinetic parameter estimates following administration of valacyclovir hydrochloride to healthy adult volunteers are presented in Table 3. There was less than dose-proportional increase in acyclovir maximum concentration (C max) and area under the acyclovir concentration-time curve (AUC) after single-dose and multiple-dose administration (4 times daily) of valacyclovir hydrochloride from doses between 250 mg to gram. There is no accumulation of acyclovir after the administration of valacyclovir at the recommended dosage regimens in adults with normal renal function. Table 3. Mean (+-SD) Plasma Acyclovir Pharmacokinetic Parameters Following Administration of Valacyclovir Hydrochloride to Healthy Adult Volunteers Dose Single-Dose Administration (N 8) Multiple-Dose Administration (N 24, per treatment arm) max (+-SD) (mcg/mL) AUC (+-SD) (hrmcg/mL) max (+-SD) (mcg/mL) AUC (+-SD) (hrmcg/mL) 100 mg 0.83 (+-0.14) 2.28 (+-0.40) ND ND 250 mg 2.15 (+-0.50) 5.76 (+-0.60) 2.11 (+-0.33) 5.66 (+-1.09) 500 mg 3.28 (+-0.83) 11.59 (+-1.79) 3.69 (+-0.87) 9.88 (+-2.01) 750 mg 4.17 (+-1.14) 14.11 (+-3.54) ND ND 1,000 mg 5.65 (+-2.37) 19.52 (+-6.04) 4.96 (+-0.64) 15.70 (+-2.27) Administered times daily for 11 days. ND not done. Distribution: The binding of valacyclovir to human plasma proteins ranges from 13.5% to 17.9%. The binding of acyclovir to human plasma proteins ranges from 9% to 33%. Metabolism: Valacyclovir is converted to acyclovir and L-valine by first-pass intestinal and/or hepatic metabolism. Acyclovir is converted to small extent to inactive metabolites by aldehyde oxidase and by alcohol and aldehyde dehydrogenase. Neither valacyclovir nor acyclovir is metabolized by cytochrome P450 enzymes. Plasma concentrations of unconverted valacyclovir are low and transient, generally becoming non-quantifiable by hours after administration. Peak plasma valacyclovir concentrations are generally less than 0.5 mcg/mL at all doses. After single-dose administration of gram of valacyclovir hydrochloride, average plasma valacyclovir concentrations observed were 0.5, 0.4, and 0.8 mcg/mL in patients with hepatic dysfunction, renal insufficiency, and in healthy volunteers who received concomitant cimetidine and probenecid, respectively. Elimination: The pharmacokinetic disposition of acyclovir delivered by valacyclovir is consistent with previous experience from intravenous and oral acyclovir. Following the oral administration of single gram dose of radiolabeled valacyclovir to healthy subjects, 46% and 47% of administered radioactivity was recovered in urine and feces, respectively, over 96 hours. Acyclovir accounted for 89% of the radioactivity excreted in the urine. Renal clearance of acyclovir following the administration of single gram dose of valacyclovir hydrochloride to 12 healthy volunteers was approximately 255 +- 86 mL/min which represents 42% of total acyclovir apparent plasma clearance. The plasma elimination half-life of acyclovir typically averaged 2.5 to 3.3 hours in all studies of valacyclovir hydrochloride in volunteers with normal renal function. Specific Populations: Renal Impairment: Reduction in dosage is recommended in patients with renal impairment [see Dosage and Administration (2.4), Use in Specific Populations (8.5), (8.6)]. Following administration of valacyclovir hydrochloride to volunteers with ESRD, the average acyclovir half-life is approximately 14 hours. During hemodialysis, the acyclovir half-life is approximately hours. Approximately one third of acyclovir in the body is removed by dialysis during 4-hour hemodialysis session. Apparent plasma clearance of acyclovir in dialysis patients was 86.3 +- 21.3 mL/min/1.73 2 compared with 679.16 +- 162.76 mL/min/1.73 2 in healthy volunteers. Hepatic Impairment: Administration of valacyclovir hydrochloride to patients with moderate (biopsy-proven cirrhosis) or severe (with and without ascites and biopsy-proven cirrhosis)liver disease indicated that the rate but not the extent of conversion of valacyclovir to acyclovir is reduced, and the acyclovir half-life is not affected. Dosage modification is not recommended for patients with cirrhosis. HIV Disease: In patients with HIV disease and CD4+ cell counts <150 cells/mm who received valacyclovir hydrochloride at dosage of gram times daily for 30 days, the pharmacokinetics of valacyclovir and acyclovir were not different from that observed in healthy volunteers. Geriatrics: After single-dose administration of gram of valacyclovir hydrochloride in healthy geriatric volunteers, the half-life of acyclovir was 3.11 +- 0.51 hours, compared with 2.91 +- 0.63 hours in healthy younger adult volunteers. The pharmacokinetics of acyclovir following single- and multiple-dose oral administration of valacyclovir hydrochloride in geriatric volunteers varied with renal function. Dose reduction may be required in geriatric patients, depending on the underlying renal status of the patient [see Dosage and Administration (2.4), Use in Specific Populations (8.5), (8.6)]. Pediatrics: Acyclovir pharmacokinetics have been evaluated in total of 98 pediatric patients (1 month to <12 years of age) following administration of the first dose of an extemporaneous oral suspension of valacyclovir [see Adverse Reactions (6.2), Use in Specific Populations (8.4)]. Acyclovir pharmacokinetic parameter estimates following 20 mg/kg dose are provided in Table 4. Table 4. Mean (+-SD) Plasma Acyclovir Pharmacokinetic Parameter Estimates Following First-Dose Administration of 20 mg/kg Valacyclovir Oral Suspension to Pediatric Patients vs. Gram Single Dose of Valacyclovir Hydrochloride to Adults Parameter Pediatric Patients (20 mg/kg Oral Suspension) Adults gram Solid Dose of Valacyclovir Hydrochloride (N 15) - <2 yr (N 6) - <6 yr (N 12) - <12 yr (N 8) AUC (mcgohr/mL) 14.4 (+-6.26) 10.1 (+-3.35) 13.1 (+-3.43) 17.2 (+-3.10) Cmax (mcg/mL) 4.03 (+-1.37) 3.75 (+-1.14) 4.71 (+-1.20) 4.72 (+-1.37) Historical estimates using pediatric pharmacokinetic sampling schedule. Drug Interactions: When valacyclovir hydrochloride is coadministered with antacids, cimetidine and/or probenicid, digoxin, or thiazide diuretics in patients with normal renal function, the effects are not considered to be of clinical significance (see below). Therefore, when valacyclovir hydrochloride is coadministered with these drugs in patients with normal renal function, no dosage adjustment is recommended. Antacids: The pharmacokinetics of acyclovir after single dose of valacyclovir hydrochloride (1 gram) were unchanged by coadministration of single dose of antacids (Al 3+ or Mg ++). Cimetidine: Acyclovir max and AUC following single dose of valacyclovir hydrochloride (1 gram) increased by 8% and 32%, respectively, after single dose of cimetidine (800 mg). Cimetidine Plus Probenecid: Acyclovir max and AUC following single dose of valacyclovir hydrochloride (1 gram) increased by 30% and 78%, respectively, after combination of cimetidine and probenecid, primarily due to reduction in renal clearance of acyclovir. Digoxin: The pharmacokinetics of digoxin were not affected by coadministration of valacyclovir hydrochloride gram times daily, and the pharmacokinetics of acyclovir after single dose of valacyclovir hydrochloride (1 gram) was unchanged by coadministration of digoxin (2 doses of 0.75 mg). Probenecid: Acyclovir max and AUC following single dose of valacyclovir hydrochloride (1 gram) increased by 22% and 49%, respectively, after probenecid (1 gram). Thiazide Diuretics: The pharmacokinetics of acyclovir after single dose of valacyclovir hydrochloride (1 gram) were unchanged by coadministration of multiple doses of thiazide diuretics.

ADVERSE REACTIONS SECTION.

6 ADVERSE REACTIONS. The following serious adverse reactions are discussed in greater detail in other sections of the labeling: Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome [see Warnings and Precautions (5.1)]. Acute Renal Failure [see Warnings and Precautions (5.2)]. Central Nervous System Effects [see Warnings and Precautions (5.3)]. The most common adverse reactions reported in at least indication by >10% of adult patients treated with valacyclovir hydrochloride and observed more frequently with valacyclovir hydrochloride compared to placebo are headache, nausea, and abdominal pain. The only adverse reaction reported in >10% of pediatric patients <18 years of age was headache. o The most common adverse reactions reported in at least one indication by >10% of adult patients treated with valacyclovir hydrochloride and more commonly than in patients treated with placebo are headache, nausea, and abdominal pain. (6.1) The only adverse reaction occurring in >10% of pediatric patients <18 years of age was headache.(6.2) To report SUSPECTED ADVERSE REACTIONS, contact Hetero Labs Limited at 866-495-1995 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling 6.1 Clinical Trials Experience in Adult Patients. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice. Cold Sores (Herpes Labialis): In clinical studies for the treatment of cold sores, the adverse reactions reported by patients receiving valacyclovir hydrochloride grams twice daily (n 609) or placebo (n 609) for day, respectively, included headache (14%, 10%) and dizziness (2%, 1%). The frequencies of abnormal ALT (>2 ULN) were 1.8% for patients receiving valacyclovir hydrochloride compared with 0.8% for placebo. Other laboratory abnormalities (hemoglobin, white blood cells, alkaline phosphatase, and serum creatinine) occurred with similar frequencies in the groups. Genital Herpes: Initial Episode: In clinical study for the treatment of initial episodes of genital herpes, the adverse reactions reported by >=5% of patients receiving valacyclovir hydrochloride gram twice daily for 10 days (n 318) or oral acyclovir 200 mg times daily for 10 days (n 318), respectively, included headache (13%, 10%) and nausea (6%, 6%). For the incidence of laboratory abnormalities see Table 2. Recurrent Episodes: In clinical studies for the episodic treatment of recurrent genital herpes, the adverse reactions reported by >=5% of patients receiving valacyclovir hydrochloride 500 mg twice daily for days (n 402), valacyclovir hydrochloride 500 mg twice daily for days (n 1,136) or placebo (n 259), respectively, included headache (16%, 11%, 14%) and nausea (5%, 4%, 5%). For the incidence of laboratory abnormalities see Table 2. Suppressive Therapy: Suppression of Recurrent Genital Herpes in Immunocompetent Adults: In clinical study for the suppression of recurrent genital herpes infections, the adverse reactions reported by patients receiving valacyclovir hydrochloride gram once daily (n 269), valacyclovir hydrochloride 500 mg once daily (n 266), or placebo (n 134), respectively, included headache (35%, 38%, 34%), nausea (11%, 11%, 8%), abdominal pain (11%, 9%, 6%), dysmenorrhea (8%, 5%, 4%), depression (7%, 5%, 5%), arthralgia (6%, 5%, 4%), vomiting (3%, 3%, 2%), and dizziness (4%, 2%, 1%). For the incidence of laboratory abnormalities see Table 2. Suppression of Recurrent Genital Herpes in HIV-Infected Patients: In HIV-infected patients, frequently reported adverse reactions for valacyclovir hydrochloride (500 mg twice daily; = 194, median days on therapy 172) and placebo (n 99, median days on therapy 59), respectively, included headache (13%, 8%), fatigue (8%, 5%), and rash (8%, 1%). Post-randomization laboratory abnormalities that were reported more frequently in valacyclovir subjects versus placebo included elevated alkaline phosphatase (4%, 2%), elevated ALT (14%, 10%), elevated AST (16%, 11%), decreased neutrophil counts (18%, 10%), and decreased platelet counts (3%, 0%), respectively. Reduction of Transmission: In clinical study for the reduction of transmission of genital herpes, the adverse reactions reported by patients receiving valacyclovir hydrochloride 500 mg once daily (n 743) or placebo once daily (n 741), respectively, included headache (29%, 26%), nasopharyngitis (16%, 15%), and upper respiratory tract infection (9%, 10%). Herpes Zoster: In clinical studies for the treatment of herpes zoster, the adverse reactions reported by patients receiving valacyclovir hydrochloride gram times daily for to 14 days (n 967) or placebo (n 195), respectively, included nausea (15%, 8%), headache (14%, 12%), vomiting (6%, 3%), dizziness (3%, 2%), and abdominal pain (3%, 2%). For the incidence of laboratory abnormalities see Table 2. Table 2. Incidence (%) of Laboratory Abnormalities in Herpes Zoster and Genital Herpes Study Populations Laboratory Abnormality Herpes Zoster Genital Herpes Treatment Genital Herpes Suppression Valacyclovir Hydrochloride gram times daily (n 967) Placebo (n 195) Valacyclovir Hydrochloride gram twice daily (n 1,194) Valacyclovir Hydrochloride 500 mg twice daily (n 1,159) Placebo (n 439) Valacyclovir Hydrochloride gram once daily (n 269) Valacyclovir Hydrochloride 500 mg once daily (n 266) Placebo (n 134) Hemoglobin (<0.8 LLN) 0.8% 0% 0.3% 0.2% 0% 0% 0.8% 0.8% White blood cells (<0.75 LLN) 1.3% 0.6% 0.7% 0.6% 0.2% 0.7% 0.8% 1.5% Platelet count (<100,000/mm 3) 1.0% 1.2% 0.3% 0.1% 0.7% 0.4% 1.1% 1.5% AST (SGOT) (>2 ULN) 1.0% 0% 1.0% 0.5% 4.1% 3.8% 3.0% Serum creatinine (>1.5 ULN) 0.2% 0% 0.7% 0% 0% 0% 0% 0% Data were not collected prospectively. LLN Lower limit of normal. ULN Upper limit of normal. 6.2 Clinical Trials Experience in Pediatric Patients. The safety profile of valacyclovir hydrochloride has been studied in 177 pediatric patients month to <18 years of age. Sixty-five pediatric patients, 12 to <18 years of age, received oral tablets for to days for treatment of cold sores. The remaining 112 pediatric patients, month to <12 years of age, participated in pharmacokinetic and safety studies and received valacyclovir oral suspension. Fifty-one of these 112 pediatric patients received oral suspension for to days. The frequency, intensity, and nature of clinical adverse reactions and laboratory abnormalities were similar to those seen in adults. Pediatric Patients 12 to <18 Years of Age (Cold Sores): In clinical studies for the treatment of cold sores, the adverse reactions reported by adolescent patients receiving valacyclovir hydrochloride grams twice daily for day, or valacyclovir hydrochloride grams twice daily for day followed by gram twice daily for day (n 65, across both dosing groups), or placebo (n 30), respectively, included headache (17%, 3%) and nausea (8%, 0%). Pediatric Patients Month to <12 Years of Age: Adverse events reported in more than subject across the pharmacokinetic and safety studies in children month to <12 years of age were diarrhea (5%), pyrexia (4%), dehydration (2%), herpes simplex (2%), and rhinorrhea (2%). No clinically meaningful changes in laboratory values were observed. 6.3 Postmarketing Experience. In addition to adverse events reported from clinical trials, the following events have been identified during postmarketing use of valacyclovir hydrochloride. Because they are reported voluntarily from population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to combination of their seriousness, frequency of reporting, or potential causal connection to valacyclovir hydrochloride. General: Facial edema, hypertension, tachycardia. Allergic: Acute hypersensitivity reactions including anaphylaxis, angioedema, dyspnea, pruritus, rash, and urticaria [see Contraindications (4)]. CNS Symptoms: Aggressive behavior; agitation; ataxia; coma; confusion; decreased consciousness; dysarthria; encephalopathy; mania; and psychosis, including auditory and visual hallucinations, seizures, tremors [see Warnings and Precautions (5.3), Use in Specific Populations (8.5), (8.6)]. Eye: Visual abnormalities. Gastrointestinal: Diarrhea. Hepatobiliary Tract and Pancreas: Liver enzyme abnormalities, hepatitis. Renal: Renal failure, renal pain (may be associated with renal failure) [see Warnings and Precautions (5.2), Use in Specific Populations (8.5), (8.6)]. Hematologic: Thrombocytopenia, aplastic anemia, leukocytoclastic vasculitis, TTP/HUS [see Warnings and Precautions (5.1)]. Skin: Erythema multiforme, rashes including photosensitivity, alopecia.

CLINICAL PHARMACOLOGY SECTION.

12 CLINICAL PHARMACOLOGY. 12.1 Mechanism of Action. Valacyclovir is an antiviral drug [see Clinical Pharmacology (12.4)]. 12.3 Pharmacokinetics. The pharmacokinetics of valacyclovir and acyclovir after oral administration of valacyclovir hydrochloride have been investigated in 14 volunteer studies involving 283 adults and in studies involving 112 pediatric subjects from month to <12 years of age. Pharmacokinetics in Adults: Absorption and Bioavailability: After oral administration, valacyclovir hydrochloride is rapidly absorbed from the gastrointestinal tract and nearly completely converted to acyclovir and L-valine by first-pass intestinal and/or hepatic metabolism. The absolute bioavailability of acyclovir after administration of valacyclovir hydrochloride is 54.5% +- 9.1% as determined following 1 gram oral dose of valacyclovir hydrochloride and 350 mg intravenous acyclovir dose to 12 healthy volunteers. Acyclovir bioavailability from the administration of valacyclovir hydrochloride is not altered by administration with food(30 minutes after an 873 Kcal breakfast, which included 51 grams of fat). Acyclovir pharmacokinetic parameter estimates following administration of valacyclovir hydrochloride to healthy adult volunteers are presented in Table 3. There was less than dose-proportional increase in acyclovir maximum concentration (C max) and area under the acyclovir concentration-time curve (AUC) after single-dose and multiple-dose administration (4 times daily) of valacyclovir hydrochloride from doses between 250 mg to gram. There is no accumulation of acyclovir after the administration of valacyclovir at the recommended dosage regimens in adults with normal renal function. Table 3. Mean (+-SD) Plasma Acyclovir Pharmacokinetic Parameters Following Administration of Valacyclovir Hydrochloride to Healthy Adult Volunteers Dose Single-Dose Administration (N 8) Multiple-Dose Administration (N 24, per treatment arm) max (+-SD) (mcg/mL) AUC (+-SD) (hrmcg/mL) max (+-SD) (mcg/mL) AUC (+-SD) (hrmcg/mL) 100 mg 0.83 (+-0.14) 2.28 (+-0.40) ND ND 250 mg 2.15 (+-0.50) 5.76 (+-0.60) 2.11 (+-0.33) 5.66 (+-1.09) 500 mg 3.28 (+-0.83) 11.59 (+-1.79) 3.69 (+-0.87) 9.88 (+-2.01) 750 mg 4.17 (+-1.14) 14.11 (+-3.54) ND ND 1,000 mg 5.65 (+-2.37) 19.52 (+-6.04) 4.96 (+-0.64) 15.70 (+-2.27) Administered times daily for 11 days. ND not done. Distribution: The binding of valacyclovir to human plasma proteins ranges from 13.5% to 17.9%. The binding of acyclovir to human plasma proteins ranges from 9% to 33%. Metabolism: Valacyclovir is converted to acyclovir and L-valine by first-pass intestinal and/or hepatic metabolism. Acyclovir is converted to small extent to inactive metabolites by aldehyde oxidase and by alcohol and aldehyde dehydrogenase. Neither valacyclovir nor acyclovir is metabolized by cytochrome P450 enzymes. Plasma concentrations of unconverted valacyclovir are low and transient, generally becoming non-quantifiable by hours after administration. Peak plasma valacyclovir concentrations are generally less than 0.5 mcg/mL at all doses. After single-dose administration of gram of valacyclovir hydrochloride, average plasma valacyclovir concentrations observed were 0.5, 0.4, and 0.8 mcg/mL in patients with hepatic dysfunction, renal insufficiency, and in healthy volunteers who received concomitant cimetidine and probenecid, respectively. Elimination: The pharmacokinetic disposition of acyclovir delivered by valacyclovir is consistent with previous experience from intravenous and oral acyclovir. Following the oral administration of single gram dose of radiolabeled valacyclovir to healthy subjects, 46% and 47% of administered radioactivity was recovered in urine and feces, respectively, over 96 hours. Acyclovir accounted for 89% of the radioactivity excreted in the urine. Renal clearance of acyclovir following the administration of single gram dose of valacyclovir hydrochloride to 12 healthy volunteers was approximately 255 +- 86 mL/min which represents 42% of total acyclovir apparent plasma clearance. The plasma elimination half-life of acyclovir typically averaged 2.5 to 3.3 hours in all studies of valacyclovir hydrochloride in volunteers with normal renal function. Specific Populations: Renal Impairment: Reduction in dosage is recommended in patients with renal impairment [see Dosage and Administration (2.4), Use in Specific Populations (8.5), (8.6)]. Following administration of valacyclovir hydrochloride to volunteers with ESRD, the average acyclovir half-life is approximately 14 hours. During hemodialysis, the acyclovir half-life is approximately hours. Approximately one third of acyclovir in the body is removed by dialysis during 4-hour hemodialysis session. Apparent plasma clearance of acyclovir in dialysis patients was 86.3 +- 21.3 mL/min/1.73 2 compared with 679.16 +- 162.76 mL/min/1.73 2 in healthy volunteers. Hepatic Impairment: Administration of valacyclovir hydrochloride to patients with moderate (biopsy-proven cirrhosis) or severe (with and without ascites and biopsy-proven cirrhosis)liver disease indicated that the rate but not the extent of conversion of valacyclovir to acyclovir is reduced, and the acyclovir half-life is not affected. Dosage modification is not recommended for patients with cirrhosis. HIV Disease: In patients with HIV disease and CD4+ cell counts <150 cells/mm who received valacyclovir hydrochloride at dosage of gram times daily for 30 days, the pharmacokinetics of valacyclovir and acyclovir were not different from that observed in healthy volunteers. Geriatrics: After single-dose administration of gram of valacyclovir hydrochloride in healthy geriatric volunteers, the half-life of acyclovir was 3.11 +- 0.51 hours, compared with 2.91 +- 0.63 hours in healthy younger adult volunteers. The pharmacokinetics of acyclovir following single- and multiple-dose oral administration of valacyclovir hydrochloride in geriatric volunteers varied with renal function. Dose reduction may be required in geriatric patients, depending on the underlying renal status of the patient [see Dosage and Administration (2.4), Use in Specific Populations (8.5), (8.6)]. Pediatrics: Acyclovir pharmacokinetics have been evaluated in total of 98 pediatric patients (1 month to <12 years of age) following administration of the first dose of an extemporaneous oral suspension of valacyclovir [see Adverse Reactions (6.2), Use in Specific Populations (8.4)]. Acyclovir pharmacokinetic parameter estimates following 20 mg/kg dose are provided in Table 4. Table 4. Mean (+-SD) Plasma Acyclovir Pharmacokinetic Parameter Estimates Following First-Dose Administration of 20 mg/kg Valacyclovir Oral Suspension to Pediatric Patients vs. Gram Single Dose of Valacyclovir Hydrochloride to Adults Parameter Pediatric Patients (20 mg/kg Oral Suspension) Adults gram Solid Dose of Valacyclovir Hydrochloride (N 15) - <2 yr (N 6) - <6 yr (N 12) - <12 yr (N 8) AUC (mcgohr/mL) 14.4 (+-6.26) 10.1 (+-3.35) 13.1 (+-3.43) 17.2 (+-3.10) Cmax (mcg/mL) 4.03 (+-1.37) 3.75 (+-1.14) 4.71 (+-1.20) 4.72 (+-1.37) Historical estimates using pediatric pharmacokinetic sampling schedule. Drug Interactions: When valacyclovir hydrochloride is coadministered with antacids, cimetidine and/or probenicid, digoxin, or thiazide diuretics in patients with normal renal function, the effects are not considered to be of clinical significance (see below). Therefore, when valacyclovir hydrochloride is coadministered with these drugs in patients with normal renal function, no dosage adjustment is recommended. Antacids: The pharmacokinetics of acyclovir after single dose of valacyclovir hydrochloride (1 gram) were unchanged by coadministration of single dose of antacids (Al 3+ or Mg ++). Cimetidine: Acyclovir max and AUC following single dose of valacyclovir hydrochloride (1 gram) increased by 8% and 32%, respectively, after single dose of cimetidine (800 mg). Cimetidine Plus Probenecid: Acyclovir max and AUC following single dose of valacyclovir hydrochloride (1 gram) increased by 30% and 78%, respectively, after combination of cimetidine and probenecid, primarily due to reduction in renal clearance of acyclovir. Digoxin: The pharmacokinetics of digoxin were not affected by coadministration of valacyclovir hydrochloride gram times daily, and the pharmacokinetics of acyclovir after single dose of valacyclovir hydrochloride (1 gram) was unchanged by coadministration of digoxin (2 doses of 0.75 mg). Probenecid: Acyclovir max and AUC following single dose of valacyclovir hydrochloride (1 gram) increased by 22% and 49%, respectively, after probenecid (1 gram). Thiazide Diuretics: The pharmacokinetics of acyclovir after single dose of valacyclovir hydrochloride (1 gram) were unchanged by coadministration of multiple doses of thiazide diuretics. 12.4 Microbiology. Mechanism of Action: Valacyclovir is nucleoside analogue DNA polymerase inhibitor. Valacyclovir hydrochloride is rapidly converted to acyclovir which has demonstrated antiviral activity against HSV types (HSV-1) and (HSV-2) and VZV both in cell culture and in vivo. The inhibitory activity of acyclovir is highly selective due to its affinity for the enzyme thymidine kinase (TK )encoded by HSV and VZV. This viral enzyme converts acyclovir into acyclovir monophosphate, nucleotide analogue. The monophosphate is further converted into diphosphate by cellular guanylate kinase and into triphosphate by number of cellular enzymes. In biochemical assays, acyclovir triphosphate inhibits replication of herpes viral DNA. This is accomplished in ways: 1)competitive inhibition of viral DNA polymerase, 2)incorporation and termination of the growing viral DNA chain, and 3)inactivation of the viral DNA polymerase. The greater antiviral activity of acyclovir against HSV compared with VZV is due to its more efficient phosphorylation by the viral TK. Antiviral Activities: The quantitative relationship between the cell culture susceptibility of herpesviruses to antivirals and the clinical response to therapy has not been established in humans, and virus sensitivity testing has not been standardized. Sensitivity testing results, expressed as the concentration of drug required to inhibit by 50% the growth of virus in cell culture (EC 50), vary greatly depending upon number of factors. Using plaque-reduction assays, the EC 50 values against herpes simplex virus isolates range from 0.09 to 60 uM (0.02 to 13.5 mcg/mL)for HSV-1 and from 0.04 to 44 uM (0.01 to 9.9 mcg/mL)for HSV-2. The EC 50 values for acyclovir against most laboratory strains and clinical isolates of VZV range from 0.53 to 48 uM (0.12 to 10.8 mcg/mL). Acyclovir also demonstrates activity against the Oka vaccine strain of VZV with mean EC 50 of uM (1.35 mcg/mL). Resistance: Resistance of HSV and VZV to acyclovir can result from qualitative and quantitative changes in the viral TK and/or DNA polymerase. Clinical isolates of VZV with reduced susceptibility to acyclovir have been recovered from patients with AIDS. In these cases, TK-deficient mutants of VZV have been recovered. Resistance of HSV and VZV to acyclovir occurs by the same mechanisms. While most of the acyclovir-resistant mutants isolated thus far from immunocompromised patients have been found to be TK-deficient mutants, other mutants involving the viral TK gene (TK partial and TK altered) and DNA polymerase have also been isolated. TK-negative mutants may cause severe disease in immunocompromised patients. The possibility of viral resistance to valacyclovir (and therefore, to acyclovir) should be considered in patients who show poor clinical response during therapy.

CLINICAL STUDIES SECTION.

14 CLINICAL STUDIES. 14.1 Cold Sores (Herpes Labialis). Two double-blind, placebo-controlled clinical trials were conducted in 1,856 healthy adults and adolescents (>=12 years old) with history of recurrent cold sores. Patients self-initiated therapy at the earliest symptoms and prior to any signs of cold sore. The majority of patients initiated treatment within hours of onset of symptoms. Patients were randomized to valacyclovir hydrochloride grams twice daily on Day followed by placebo on Day 2, valacyclovir hydrochloride grams twice daily on Day followed by gram twice daily on Day 2, or placebo on Days and 2. The mean duration of cold sore episodes was about day shorter in treated subjects as compared with placebo. The day regimen did not offer additional benefit over the 1-day regimen. No significant difference was observed between subjects receiving valacyclovir hydrochloride or placebo in the prevention of progression of cold sore lesions beyond the papular stage. 14.2 Genital Herpes Infections. Initial Episode: Six hundred forty-three immunocompetent adults with first-episode genital herpes who presented within 72 hours of symptom onset were randomized in double-blind trial to receive 10 days of valacyclovir hydrochloride gram twice daily (n 323) or oral acyclovir 200 mg times day (n 320). For both treatment groups: the median time to lesion healing was days, the median time to cessation of pain was days, the median time to cessation of viral shedding was days. Recurrent Episodes: Three double-blind trials (2 of them placebo-controlled) in immunocompetent adults with recurrent genital herpes were conducted. Patients self-initiated therapy within 24 hours of the first sign or symptom of recurrent genital herpes episode. In study, patients were randomized to receive days of treatment with either valacyclovir hydrochloride 500 mg twice daily (n 360) or placebo (n 259). The median time to lesion healing was days in the group receiving valacyclovir hydrochloride 500 mg versus days in the placebo group, and the median time to cessation of viral shedding in patients with at least positive culture (42% of the overall study population) was days in the group receiving valacyclovir hydrochloride 500 mg versus days in the placebo group. The median time to cessation of pain was days in the group receiving valacyclovir hydrochloride 500 mg versus days in the placebo group. Results supporting efficacy were replicated in second trial. In third study, patients were randomized to receive valacyclovir hydrochloride 500 mg twice daily for days (n 398) or valacyclovir hydrochloride 500 mg twice daily for days (and matching placebo twice daily for additional days) (n 402). The median time to lesion healing was about 1/2 days in both treatment groups. The median time to cessation of pain was about days in both treatment groups. Suppressive Therapy: Two clinical studies were conducted, one in immunocompetent adults and one in HIV-infected adults. double-blind, 12-month, placebo- and active-controlled study enrolled immunocompetent adults with history of or more recurrences per year. Outcomes for the overall study population are shown in Table 5. Table 5. Recurrence Rates in Immunocompetent Adults at and 12 Months Outcome Months 12 Months Valacyclovir Hydrochloride gram once daily (n 269) Oral acyclovir 400 mg twice daily (n 267) Placebo (n 134) Valacyclovir Hydrochloride gram once daily (n 269) Oral acyclovir 400 mg twice daily (n 267) Placebo (n 134) Recurrence free 55% 54% 7% 34% 34% 4% Recurrences 35% 36% 83% 46% 46% 85% Unknown 10% 10% 10% 19% 19% 10% Includes lost to follow-up, discontinuations due to adverse events, and consent withdrawn. Subjects with or fewer recurrences per year showed comparable results with valacyclovir hydrochloride 500 mg once daily. In second study, 293 HIV-infected adults on stable antiretroviral therapy with history of or more recurrences of ano-genital herpes per year were randomized to receive either valacyclovir hydrochloride 500 mg twice daily (n 194) or matching placebo (n 99) for months. The median duration of recurrent genital herpes in enrolled subjects was years, and the median number of recurrences in the year prior to enrollment was 5. Overall, the median prestudy HIV-1 RNA was 2.6 log10 copies/mL. Among patients who received valacyclovir hydrochloride, the prestudy median CD4+ cell count was 336 cells/mm 3; 11% had <100 cells/mm 3, 16% had 100 to 199 cells/mm 3, 42% had 200 to 499 cells/mm 3, and 31% had >=500 cells/mm 3. Outcomes for the overall study population are shown in Table 6. Table 6. Recurrence Rates in HIV-Infected Adults at Months Outcome Valacyclovir Hydrochloride 500 mg twice daily (n 194) Placebo (n 99) Recurrence free 65% 26% Recurrences 17% 57% Unknown 18% 17% Includes lost to follow-up, discontinuations due to adverse events, and consent withdrawn. Reduction of Transmission of Genital Herpes: double-blind, placebo-controlled study to assess transmission of genital herpes was conducted in 1,484 monogamous, heterosexual, immunocompetent adult couples. The couples were discordant for HSV-2 infection. The source partner had history of or fewer genital herpes episodes per year. Both partners were counseled on safer sex practices and were advised to use condoms throughout the study period. Source partners were randomized to treatment with either valacyclovir hydrochloride 500 mg once daily or placebo once daily for months. The primary efficacy endpoint was symptomatic acquisition of HSV-2 in susceptible partners. Overall HSV-2 acquisition was defined as symptomatic HSV-2 acquisition and/or HSV-2 seroconversion in susceptible partners. The efficacy results are summarized in Table 7. Table 7. Percentage of Susceptible Partners Who Acquired HSV-2 Defined by the Primary and Selected Secondary Endpoints Endpoint Valacyclovir Hydrochloride (n 743) Placebo (n 741) Symptomatic HSV-2 acquisition (0.5%) 16 (2.2%) HSV-2 seroconversion 12 (1.6%) 24 (3.2%) Overall HSV-2 acquisition 14 (1.9%) 27 (3.6%) Results show reductions in risk of 75% (symptomatic HSV-2 acquisition), 50% (HSV-2 seroconversion), and 48% (overall HSV-2 acquisition)with valacyclovir hydrochloride versus placebo. Individual results may vary based on consistency of safer sex practices. 14.3 Herpes Zoster. Two randomized double-blind clinical trials in immunocompetent adults with localized herpes zoster were conducted. Valacyclovir hydrochloride was compared with placebo in patients less than 50 years of age, and with oral acyclovir in patients greater than 50 years of age. All patients were treated within 72 hours of appearance of zoster rash. In patients less than 50 years of age, the median time to cessation of new lesion formation was days for those treated with valacyclovir hydrochloride compared with days for those treated with placebo. In patients greater than 50 years of age, the median time to cessation of new lesions was days in patients treated with either valacyclovir hydrochloride or oral acyclovir. In patients less than 50 years of age, no difference was found with respect to the duration of pain after healing (post-herpetic neuralgia) between the recipients of valacyclovir hydrochloride and placebo. In patients greater than 50 years of age, among the 83% who reported pain after healing (post-herpetic neuralgia), the median duration of pain after healing [95% confidence interval] in days was: 40 [31, 51], 43 [36, 55], and 59 [41, 77] for 7-day valacyclovir hydrochloride, 14-day valacyclovir hydrochloride, and 7-day oral acyclovir, respectively.. 14.4 Chickenpox. The use of valacyclovir hydrochloride for treatment of chickenpox in pediatric patients to <18 years of age is based on single-dose pharmacokinetic and multiple-dose safety data from an open-label trial with valacyclovir and supported by safety and extrapolated efficacy data from randomized, double-blind, placebo-controlled trials evaluating oral acyclovir in pediatric patients. The single-dose pharmacokinetic and multiple-dose safety study enrolled 27 pediatric patients to <12 years of age with clinically suspected VZV infection. Each subject was dosed with valacyclovir oral suspension, 20 mg/kg times daily for days. Acyclovir systemic exposures in pediatric patients following valacyclovir oral suspension were compared with historical acyclovir systemic exposures in immunocompetent adults receiving the solid oral dosage form of valacyclovir or acyclovir for the treatment of herpes zoster. The mean projected daily acyclovir exposures in pediatric patients across all age-groups (1 to <12 years of age) were lower (C max: 13%, AUC: 30%) than the mean daily historical exposures in adults receiving valacyclovir gram times daily, but were higher (daily AUC: 50%) than the mean daily historical exposures in adults receiving acyclovir 800 mg times daily. The projected daily exposures in pediatric patients were greater (daily AUC approximately 100% greater) than the exposures seen in immunocompetent pediatric patients receiving acyclovir 20 mg/kg times daily for the treatment of chickenpox. Based on the pharmacokinetic and safety data from this study and the safety and extrapolated efficacy data from the acyclovir studies, oral valacyclovir 20 mg/kg times day for days (not to exceed gram times daily) is recommended for the treatment of chickenpox in pediatric patients to <18 years of age. Because the efficacy and safety of acyclovir for the treatment of chickenpox in children <2 years of age have not been established, efficacy data cannot be extrapolated to support valacyclovir treatment in children <2 years of age with chickenpox. Valacyclovir is also not recommended for the treatment of herpes zoster in children because safety data up to days duration are not available [see Use in Specific Populations (8.4)].

DOSAGE & ADMINISTRATION SECTION.

2 DOSAGE ADMINISTRATION. Valacyclovir tablets, USP may be given without regard to meals. Valacyclovir oral suspension (25 mg/mL or 50 mg/mL) may be prepared extemporaneously from 500 mg valacyclovir tablets, USP for use in pediatric patients for whom solid dosage form is not appropriate [see Dosage and Administration (2.3)]. Adult Dosage (2.1) Cold Sores grams every 12 hours for day Genital Herpes Initial episode gram twice daily for 10 days Recurrent episodes 500 mg twice daily for days Suppressive therapy Immunocompetent patients gram once daily Alternate dose in patients with <=9 recurrnces/yr 500 mg once daily HIV-infected patients 500 mg twice daily Reduction of transmission 500 mg once daily Herpes Zoster gram times daily for days Pediatric Dosage (2.2) Cold Sores (>=12 years of age) grams every 12 hours for day Chickenpox (2 to <18 years of age) 20 mg/kg times daily for days; not to exceed gram times daily Valacyclovir oral suspension (25 mg/mL or 50 mg/mL) can be prepared from the 500 mg valacyclovir tablets, USP. (2.3). 2.1 Adult Dosing Recommendations. Cold Sores (Herpes Labialis): The recommended dosage of valacyclovir tablets, USP for treatment of cold sores is grams twice daily for day taken 12 hours apart. Therapy should be initiated at the earliest symptom of cold sore (e.g., tingling, itching, or burning). Genital Herpes: Initial Episode: The recommended dosage of valacyclovir tablets, USP for treatment of initial genital herpes is gram twice daily for 10 days. Therapy was most effective when administered within 48 hours of the onset of signs and symptoms. Recurrent Episodes: The recommended dosage of valacyclovir tablets, USP for treatment of recurrent genital herpes is 500 mg twice daily for days. Initiate treatment at the first sign or symptom of an episode. Suppressive Therapy: The recommended dosage of valacyclovir tablets, USP for chronic suppressive therapy of recurrent genital herpes is gram once daily in patients with normal immune function. In patients with history of or fewer recurrences per year, an alternative dose is 500 mg once daily. In HIV-infected patients with CD4+ cell count >=100 cells/mm 3, the recommended dosage of valacyclovir tablets, USP for chronic suppressive therapy of recurrent genital herpes is 500 mg twice daily. Reduction of Transmission: The recommended dosage of valacyclovir tablets, USP for reduction of transmission of genital herpes in patients with history of or fewer recurrences per year is 500 mg once daily for the source partner. Herpes Zoster: The recommended dosage of valacyclovir tablets, USP for treatment of herpes zoster is gram times daily for days. Therapy should be initiated at the earliest sign or symptom of herpes zoster and is most effective when started within 48 hours of the onset of rash. 2.2 Pediatric Dosing Recommendations. Cold Sores (Herpes Labialis): The recommended dosage of valacyclovir tablets, USP for the treatment of cold sores in pediatric patients >=12 years of age is grams twice daily for day taken 12 hours apart. Therapy should be initiated at the earliest symptom of cold sore (e.g., tingling, itching, or burning). Chickenpox: The recommended dosage of valacyclovir tablets, USP for treatment of chickenpox in immunocompetent pediatric patients to <18 years of age is 20 mg/kg administered times daily for days. The total dose should not exceed gram times daily. Therapy should be initiated at the earliest sign or symptom [see Use in Specific Populations (8.4), Clinical Pharmacology (12.3), Clinical Studies (14.4)]. 2.3 Extemporaneous Preparation of Oral Suspension. Ingredients and Preparation per USP-NF: valacyclovir tablets, USP 500 mg, cherry flavor, and Suspension Structured Vehicle USP-NF (SSV). Valacyclovir oral suspension (25 mg/mL or 50 mg/mL) should be prepared in lots of 100 mL. Prepare Suspension at Time of Dispensing as Follows: Prepare SSV according to the USP-NF. Using pestle and mortar, grind the required number of valacyclovir tablets, USP 500 mg until fine powder is produced (5 valacyclovir tablets, USP for 25 mg/mL suspension; 10 valacyclovir tablets, USP for 50 mg/mL suspension). Gradually add approximately mL aliquots of SSV to the mortar and triturate the powder until paste has been produced. Ensure that the powder has been adequately wetted. Continue to add approximately mL aliquots of SSV to the mortar, mixing thoroughly between additions, until concentrated suspension is produced, to minimum total quantity of 20 mL SSV and maximum total quantity of 40 mL SSV for both the 25 mg/mL and 50 mg/mL suspensions. Transfer the mixture to suitable 100 mL measuring flask. Transfer the cherry flavor to the mortar and dissolve in approximately mL of SSV. Once dissolved, add to the measuring flask. Rinse the mortar at least times with approximately mL aliquots of SSV, transferring the rinsing to the measuring flask between additions. Make the suspension to volume (100 mL) with SSV and shake thoroughly to mix. Transfer the suspension to an amber glass medicine bottle with child-resistant closure. The prepared suspension should be labeled with the following information Shake well before using. Store suspension between to 8C (36 to 46F) in refrigerator. Discard after 28 days. The amount of cherry flavor added is as instructed by the suppliers of the cherry flavor. 2.4 Patients with Renal impairment. Dosage recommendations for adult patients with reduced renal function are provided in Table [see Use in Specific Populations (8.5, 8.6), Clinical Pharmacology (12.3)]. Data are not available for the use of valacyclovir tablets, USP in pediatric patients with creatinine clearance <50 mL/min/1.73 2. Table 1. Valacyclovir Tablets, USP Dosage Recommendations for Adults With Renal Impairment Indications Normal Dosage Regimen (Creatinine Clearance >=50 mL/min) Creatinine Clearance (mL/min) 30-49 10-29 <10 Cold sores (Herpes labialis)Do not exceed day of treatment.Two gram doses taken 12 hours apart Two gram doses taken 12 hours apart Two 500 mg doses taken 12 hours apart 500 mg single dose Genital herpes: Initial episode1 gram every 12 hours no reduction gram every 24 hours 500 mg every 24 hours Genital herpes: Recurrent episode500 mg every 12 hours no reduction 500 mg every 24 hours 500 mg every 24 hours Indications Normal Dosage Regimen (Creatinine Clearance >=50 mL/min) Creatinine Clearance (mL/min) 30-49 10-29 <10 Genital herpes: Suppressive therapy Immunocompetent patients gram every 24 hours no reduction 500 mg every 24 hours 500 mg every 24 hours Alternate dose for immunocompetent patients with <=9 recurrences/year 500 mg every 24 hours no reduction 500 mg every 48 hours 500 mg every 48 hours HIV-infected patients 500 mg every 12 hours no reduction 500 mg every 24 hours 500 mg every 24 hours Herpes zoster gram every hours gram every 12 hours gram every 24 hours 500 mg every 24 hours Hemodialysis: Patients requiring hemodialysis should receive the recommended dose of valacyclovir tablets, USP after hemodialysis. During hemodialysis, the half-life of acyclovir after administration of valacyclovir tablets, USP is approximately hours. About one third of acyclovir in the body is removed by dialysis during 4-hour hemodialysis session. Peritoneal Dialysis: There is no information specific to administration of valacyclovir tablets, USP in patients receiving peritoneal dialysis. The effect of chronic ambulatory peritoneal dialysis (CAPD) and continuous arteriovenous hemofiltration/dialysis (CAVHD) on acyclovir pharmacokinetics has been studied. The removal of acyclovir after CAPD and CAVHD is less pronounced than with hemodialysis, and the pharmacokinetic parameters closely resemble those observed in patients with end-stage renal disease (ESRD) not receiving hemodialysis. Therefore, supplemental doses of valacyclovir tablets, USP should not be required following CAPD or CAVHD.

INDICATIONS & USAGE SECTION.

1 INDICATIONS USAGE. Valacyclovir tablet, USP is nucleoside analogue DNA polymerase inhibitor indicated for: Adult Patients (1.1) Cold Sores (Herpes Labialis) Genital Herpes Treatment in immunocompetent patients (initial or recurrent episode) Suppression in immunocompetent or HIV-infected patients Reduction of transmission Herpes Zoster Pediatric Patients (1.2) Cold Sores (Herpes Labialis) Chickenpox Limitations of Use (1.3) The efficacy and safety of valacyclovir tablets, USP have not been established in immunocompromised patients other than for the suppression of genital herpes in HIV-infected patients. 1.1 Adult patients. Cold Sores (Herpes Labialis): Valacyclovir tablets, USP are indicated for treatment of cold sores (herpes labialis). The efficacy of valacyclovir tablets, USP initiated after the development of clinical signs of cold sore (e.g., papule, vesicle, or ulcer) has not been established. Genital Herpes: Initial Episode: Valacyclovir tablets, USP are indicated for treatment of the initial episode of genital herpes in immunocompetent adults. The efficacy of treatment with valacyclovir tablets, USP when initiated more than 72 hours after the onset of signs and symptoms has not been established. Recurrent Episodes: Valacyclovir tablets, USP are indicated for treatment of recurrent episodes of genital herpes in immunocompetent adults. The efficacy of treatment with valacyclovir tablets, USP when initiated more than 24 hours after the onset of signs and symptoms has not been established. Suppressive Therapy: Valacyclovir tablets, USP are indicated for chronic suppressive therapy of recurrent episodes of genital herpes in immunocompetent and in HIV-infected adults. The efficacy and safety of valacyclovir tablets, USP for the suppression of genital herpes beyond year in immunocompetent patients and beyond months in HIV-infected patients have not been established. Reduction of Transmission: Valacyclovir tablets, USP are indicated for the reduction of transmission of genital herpes in immunocompetent adults. The efficacy of valacyclovir tablets, USP for the reduction of transmission of genital herpes beyond months in discordant couples has not been established. The efficacy of valacyclovir tablets, USP for the reduction of transmission of genital herpes in individuals with multiple partners and non-heterosexual couples has not been established. Safer sex practices should be used with suppressive therapy (see current Centers for Disease Control and Prevention [CDC] Sexually Transmitted Diseases Treatment Guidelines). Herpes Zoster: Valacyclovir tablets, USP are indicated for the treatment of herpes zoster (shingles) in immunocompetent adults. The efficacy of valacyclovir tablets, USP when initiated more than 72 hours after the onset of rash and the efficacy and safety of valacyclovir tablets, USP for treatment of disseminated herpes zoster have not been established. 1.2 Pediatric Patients. Cold Sores (Herpes Labialis): Valacyclovir tablets, USP are indicated for the treatment of cold sores (herpes labialis) in pediatric patients >=12 years of age. The efficacy of valacyclovir tablets, USP initiated after the development of clinical signs of cold sore (e.g., papule, vesicle, or ulcer) has not been established. Chickenpox: Valacyclovir tablets, USP are indicated for the treatment of chickenpox in immunocompetent pediatric patients to <18 years of age. Based on efficacy data from clinical studies with oral acyclovir, treatment with valacyclovir tablets, USP should be initiated within 24 hours after the onset of rash [see Clinical Studies (14.4)]. 1.3 Limitations of Use. The efficacy and safety of valacyclovir tablets, USP have not been established in: Immunocompromised patients other than for the suppression of genital herpes in HIV-infected patients with CD4+ cell count >=100 cells/mm 3. Patients <12 years of age with cold sores (herpes labialis). Patients <2 years of age or >=18 years of age with chickenpox. Patients <18 years of age with genital herpes. Patients <18 years of age with herpes zoster. Neonates and infants as suppressive therapy following neonatal herpes simplex virus (HSV) infection.

INFORMATION FOR PATIENTS SECTION.

17 PATIENT COUNSELING INFORMATION. See FDA-Approved Patient Labeling.. 17.1 Importance of Adequate Hydration. Patients should be advised to maintain adequate hydration.. 17.2 Cold Sores (Herpes Labialis). Patients should be advised to initiate treatment at the earliest symptom of cold sore (e.g., tingling, itching, or burning). There are no data on the effectiveness of treatment initiated after the development of clinical signs of cold sore (e.g., papule, vesicle, or ulcer). Patients should be instructed that treatment for cold sores should not exceed day (2 doses) and that their doses should be taken about 12 hours apart. Patients should be informed that valacyclovir hydrochloride is not cure for cold sores.. 17.3 Genital Herpes. Patients should be informed that valacyclovir hydrochloride is not cure for genital herpes. Because genital herpes is sexually transmitted disease, patients should avoid contact with lesions or intercourse when lesions and/or symptoms are present to avoid infecting partners. Genital herpes is frequently transmitted in the absence of symptoms through asymptomatic viral shedding. Therefore, patients should be counseled to use safer sex practices in combination with suppressive therapy with valacyclovir hydrochloride. Sex partners of infected persons should be advised that they might be infected even if they have no symptoms. Type-specific serologic testing of asymptomatic partners of persons with genital herpes can determine whether risk for HSV-2 acquisition exists. Valacyclovir hydrochloride has not been shown to reduce transmission of sexually transmitted infections other than HSV-2. If medical management of genital herpes recurrence is indicated, patients should be advised to initiate therapy at the first sign or symptom of an episode. There are no data on the effectiveness of treatment initiated more than 72 hours after the onset of signs and symptoms of first episode of genital herpes or more than 24 hours after the onset of signs and symptoms of recurrent episode. There are no data on the safety or effectiveness of chronic suppressive therapy of more than years duration in otherwise healthy patients. There are no data on the safety or effectiveness of chronic suppressive therapy of more than months duration in HIV-infected patients. 17.4 Herpes Zoster. There are no data on treatment initiated more than 72 hours after onset of the zoster rash. Patients should be advised to initiate treatment as soon as possible after diagnosis of herpes zoster.. 17.5 Chickenpox. Patients should be advised to initiate treatment at the earliest sign or symptom of chickenpox.

PEDIATRIC USE SECTION.

8.4 Pediatric Use. Valacyclovir hydrochloride is indicated for treatment of cold sores in pediatric patients >=12 years of age and for treatment of chickenpox in pediatric patients to <18 years of age [see Indications and Usage(1.2, Dosage and Administration (2.2)]. The use of valacyclovir hydrochloride for treatment of cold sores is based on double-blind, placebo-controlled clinical trials in healthy adults and adolescents (>=12 years of age) with history of recurrent cold sores [see Clinical Studies (14.1)]. The use of valacyclovir hydrochloride for treatment of chickenpox in pediatric patients to <18 years of age is based on single-dose pharmacokinetic and multiple-dose safety data from an open-label trial with valacyclovir and supported by efficacy and safety data from randomized, double-blind, placebo-controlled trials evaluating oral acyclovir in pediatric patients with chickenpox [see Dosage and Administration (2.2), Adverse Reactions (6.2), Clinical Pharmacology (12.3), Clinical Studies (14.4)]. The efficacy and safety of valacyclovir have not been established in pediatric patients: <12 years of age with cold sores <18 years of age with genital herpes <18 years of age with herpes zoster <2 years of age with chickenpox for suppressive therapy following neonatal HSV infection. The pharmacokinetic profile and safety of valacyclovir oral suspension in children <12 years of age were studied in open-label studies. No efficacy evaluations were conducted in any of the studies. Study was single-dose pharmacokinetic, multiple-dose safety study in 27 pediatric patients to <12 years of age with clinically suspected varicella-zoster virus (VZV) infection [see Dosage and Administration (2.2), Adverse Reactions (6.2), Clinical Pharmacology (12.3), Clinical Studies (14.4)]. Study was single-dose pharmacokinetic and safety study in pediatric patients month to <6 years of age who had an active herpes virus infection or who were at risk for herpes virus infection. Fifty-seven subjects were enrolled and received single dose of 25 mg/kg valacyclovir oral suspension. In infants and children months to <6 years of age, this dose provided comparable systemic acyclovir exposures to that from 1 gram dose of valacyclovir in adults (historical data). In infants month to <3 months of age, mean acyclovir exposures resulting from 25 mg/kg dose were higher (Cmax: 30%, AUC: 60%) than acyclovir exposures following 1 gram dose of valacyclovir in adults. Acyclovir is not approved for suppressive therapy in infants and children following neonatal HSV infections; therefore valacyclovir is not recommended for this indication because efficacy cannot be extrapolated from acyclovir. Study was single-dose pharmacokinetic, multiple-dose safety study in 28 pediatric patients to <12 years of age with clinically suspected HSV infection. None of the children enrolled in this study had genital herpes. Each subject was dosed with valacyclovir oral suspension, 10 mg/kg twice daily for to days. Acyclovir systemic exposures in pediatric patients following valacyclovir oral suspension were compared with historical acyclovir systemic exposures in immunocompetent adults receiving the solid oral dosage form of valacyclovir or acyclovir for the treatment of recurrent genital herpes. The mean projected daily acyclovir systemic exposures in pediatric patients across all age-groups (1 to <12 years of age) were lower (Cmax: 20%, AUC: 33%) compared with the acyclovir systemic exposures in adults receiving valacyclovir 500 mg twice daily, but were higher (daily AUC: 16%) than systemic exposures in adults receiving acyclovir 200 mg times daily. Insufficient data are available to support valacyclovir for the treatment of recurrent genital herpes in this age-group because clinical information on recurrent genital herpes in young children is limited; therefore, extrapolating efficacy data from adults to this population is not possible. Moreover, valacyclovir has not been studied in children to <12 years of age with recurrent genital herpes.

SPL UNCLASSIFIED SECTION.

1.1 Adult patients. Cold Sores (Herpes Labialis): Valacyclovir tablets, USP are indicated for treatment of cold sores (herpes labialis). The efficacy of valacyclovir tablets, USP initiated after the development of clinical signs of cold sore (e.g., papule, vesicle, or ulcer) has not been established. Genital Herpes: Initial Episode: Valacyclovir tablets, USP are indicated for treatment of the initial episode of genital herpes in immunocompetent adults. The efficacy of treatment with valacyclovir tablets, USP when initiated more than 72 hours after the onset of signs and symptoms has not been established. Recurrent Episodes: Valacyclovir tablets, USP are indicated for treatment of recurrent episodes of genital herpes in immunocompetent adults. The efficacy of treatment with valacyclovir tablets, USP when initiated more than 24 hours after the onset of signs and symptoms has not been established. Suppressive Therapy: Valacyclovir tablets, USP are indicated for chronic suppressive therapy of recurrent episodes of genital herpes in immunocompetent and in HIV-infected adults. The efficacy and safety of valacyclovir tablets, USP for the suppression of genital herpes beyond year in immunocompetent patients and beyond months in HIV-infected patients have not been established. Reduction of Transmission: Valacyclovir tablets, USP are indicated for the reduction of transmission of genital herpes in immunocompetent adults. The efficacy of valacyclovir tablets, USP for the reduction of transmission of genital herpes beyond months in discordant couples has not been established. The efficacy of valacyclovir tablets, USP for the reduction of transmission of genital herpes in individuals with multiple partners and non-heterosexual couples has not been established. Safer sex practices should be used with suppressive therapy (see current Centers for Disease Control and Prevention [CDC] Sexually Transmitted Diseases Treatment Guidelines). Herpes Zoster: Valacyclovir tablets, USP are indicated for the treatment of herpes zoster (shingles) in immunocompetent adults. The efficacy of valacyclovir tablets, USP when initiated more than 72 hours after the onset of rash and the efficacy and safety of valacyclovir tablets, USP for treatment of disseminated herpes zoster have not been established.

USE IN SPECIFIC POPULATIONS SECTION.

8 USE IN SPECIFIC POPULATIONS. 8.1 Pregnancy: Teratogenic Effects. pregnancy Category B. There are no adequate and well-controlled studies of valacyclovir hydrochloride or acyclovir in pregnant women. Based on prospective pregnancy registry data on 749 pregnancies, the overall rate of birth defects in infants exposed to acyclovir in-utero appears similar to the rate for infants in the general population. Valacyclovir hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. prospective epidemiologic registry of acyclovir use during pregnancy was established in 1984 and completed in April 1999. There were 749 pregnancies followed in women exposed to systemic acyclovir during the first trimester of pregnancy resulting in 756 outcomes. The occurrence rate of birth defects approximates that found in the general population. However, the small size of the registry is insufficient to evaluate the risk for less common defects or to permit reliable or definitive conclusions regarding the safety of acyclovir in pregnant women and their developing fetuses. Animal reproduction studies performed at oral doses that provided up to 10 and times the human plasma levels during the period of major organogenesis in rats and rabbits, respectively, revealed no evidence of teratogenicity. 8.3 Nursing Mothers. Following oral administration of 500 mg dose of valacyclovir hydrochloride to nursing mothers, peak acyclovir concentrations (C max) in breast milk ranged from 0.5 to 2.3 times (median 1.4) the corresponding maternal acyclovir serum concentrations. The acyclovir breast milk AUC ranged from 1.4 to 2.6 times (median 2.2) maternal serum AUC. 500 mg maternal dosage of valacyclovir hydrochloride twice daily would provide nursing infant with an oral acyclovir dosage of approximately 0.6 mg/kg/day. This would result in less than 2% of the exposure obtained after administration of standard neonatal dose of 30 mg/kg/day of intravenous acyclovir to the nursing infant. Unchanged valacyclovir was not detected in maternal serum, breast milk, or infant urine. Caution should be exercised when valacyclovir hydrochloride is administered to nursing woman. 8.4 Pediatric Use. Valacyclovir hydrochloride is indicated for treatment of cold sores in pediatric patients >=12 years of age and for treatment of chickenpox in pediatric patients to <18 years of age [see Indications and Usage(1.2, Dosage and Administration (2.2)]. The use of valacyclovir hydrochloride for treatment of cold sores is based on double-blind, placebo-controlled clinical trials in healthy adults and adolescents (>=12 years of age) with history of recurrent cold sores [see Clinical Studies (14.1)]. The use of valacyclovir hydrochloride for treatment of chickenpox in pediatric patients to <18 years of age is based on single-dose pharmacokinetic and multiple-dose safety data from an open-label trial with valacyclovir and supported by efficacy and safety data from randomized, double-blind, placebo-controlled trials evaluating oral acyclovir in pediatric patients with chickenpox [see Dosage and Administration (2.2), Adverse Reactions (6.2), Clinical Pharmacology (12.3), Clinical Studies (14.4)]. The efficacy and safety of valacyclovir have not been established in pediatric patients: <12 years of age with cold sores <18 years of age with genital herpes <18 years of age with herpes zoster <2 years of age with chickenpox for suppressive therapy following neonatal HSV infection. The pharmacokinetic profile and safety of valacyclovir oral suspension in children <12 years of age were studied in open-label studies. No efficacy evaluations were conducted in any of the studies. Study was single-dose pharmacokinetic, multiple-dose safety study in 27 pediatric patients to <12 years of age with clinically suspected varicella-zoster virus (VZV) infection [see Dosage and Administration (2.2), Adverse Reactions (6.2), Clinical Pharmacology (12.3), Clinical Studies (14.4)]. Study was single-dose pharmacokinetic and safety study in pediatric patients month to <6 years of age who had an active herpes virus infection or who were at risk for herpes virus infection. Fifty-seven subjects were enrolled and received single dose of 25 mg/kg valacyclovir oral suspension. In infants and children months to <6 years of age, this dose provided comparable systemic acyclovir exposures to that from 1 gram dose of valacyclovir in adults (historical data). In infants month to <3 months of age, mean acyclovir exposures resulting from 25 mg/kg dose were higher (Cmax: 30%, AUC: 60%) than acyclovir exposures following 1 gram dose of valacyclovir in adults. Acyclovir is not approved for suppressive therapy in infants and children following neonatal HSV infections; therefore valacyclovir is not recommended for this indication because efficacy cannot be extrapolated from acyclovir. Study was single-dose pharmacokinetic, multiple-dose safety study in 28 pediatric patients to <12 years of age with clinically suspected HSV infection. None of the children enrolled in this study had genital herpes. Each subject was dosed with valacyclovir oral suspension, 10 mg/kg twice daily for to days. Acyclovir systemic exposures in pediatric patients following valacyclovir oral suspension were compared with historical acyclovir systemic exposures in immunocompetent adults receiving the solid oral dosage form of valacyclovir or acyclovir for the treatment of recurrent genital herpes. The mean projected daily acyclovir systemic exposures in pediatric patients across all age-groups (1 to <12 years of age) were lower (Cmax: 20%, AUC: 33%) compared with the acyclovir systemic exposures in adults receiving valacyclovir 500 mg twice daily, but were higher (daily AUC: 16%) than systemic exposures in adults receiving acyclovir 200 mg times daily. Insufficient data are available to support valacyclovir for the treatment of recurrent genital herpes in this age-group because clinical information on recurrent genital herpes in young children is limited; therefore, extrapolating efficacy data from adults to this population is not possible. Moreover, valacyclovir has not been studied in children to <12 years of age with recurrent genital herpes. 8.5 Geriatric Use. Of the total number of subjects in clinical studies of valacyclovir hydrochloride, 906 were 65 and over, and 352 were 75 and over. In clinical study of herpes zoster, the duration of pain after healing (post-herpetic neuralgia) was longer in patients 65 and older compared with younger adults. Elderly patients are more likely to have reduced renal function and require dose reduction. Elderly patients are also more likely to have renal or CNS adverse events [see Dosage and Administration (2.4), Warnings and Precautions (5.2, 5.3), Clinical Pharmacology (12.3)]. 8.6 Renal Impairment. Dosage reduction is recommended when administering valacyclovir hydrochloride to patients with renal impairment [see Dosage and Administration (2.4), Warnings and Precautions (5.2, 5.3)].

WARNINGS AND PRECAUTIONS SECTION.

5 WARNINGS AND PRECAUTIONS. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS): Has occurred in patients with advanced HIV disease and in allogenic bone marrow transplant and renal transplant patients receiving grams per day of valacyclovir hydrochloride in clinical trials. Discontinue treatment if clinical symptoms and laboratory findings consistent with TTP/HUS occur. (5.1) Acute renal failure: May occur in elderly patients (with or without reduced renal function), patients with underlying renal disease who receive higher than recommended doses of valacyclovir hydrochloride for their level of renal function, patients who receive concomitant nephrotoxic drugs, or inadequately hydrated patients. Use with caution in elderly patients and reduce dosage in patients with renal impairment. (2.4,5.2) oCentral nervous system adverse reactions (e.g., agitation, hallucinations, confusion, and encephalopathy): May occur in both adult and pediatric patients (with or without reduced renal function) and in patients with underlying renal disease who receive higher than recommended doses of valacyclovir hydrochloride for their level of renal function. Elderly patients are more likely to have central nervous system adverse reactions. Use with caution in elderly patients and reduce dosage in patients with renal impairment. (2.4, 5.3) 5.1 Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome (TTP/HUS). TTP/HUS, in some cases resulting in death, has occurred in patients with advanced HIV disease and also in allogeneic bone marrow transplant and renal transplant recipients participating in clinical trials of valacyclovir hydrochloride at doses of grams per day. Treatment with valacyclovir hydrochloride should be stopped immediately if clinical signs, symptoms, and laboratory abnormalities consistent with TTP/HUS occur.. 5.2 Acute Renal Failure. Cases of acute renal failure have been reported in: Elderly patients with or without reduced renal function. Caution should be exercised when administering valacyclovir hydrochloride to geriatric patients, and dosage reduction is recommended for those with impaired renal function [see Dosage and Administration (2.4), Use in Specific Populations (8.5)]. Patients with underlying renal disease who received higher than recommended doses of valacyclovir hydrochloride for their level of renal function. Dosage reduction is recommended when administering valacyclovir hydrochloride to patients with renal impairment [see Dosage and Administration (2.4), Use in Specific Populations (8.6)]. Patients receiving other nephrotoxic drugs. Caution should be exercised when administering valacyclovir hydrochloride to patients receiving potentially nephrotoxic drugs. Patients without adequate hydration. Precipitation of acyclovir in renal tubules may occur when the solubility (2.5 mg/mL) is exceeded in the intratubular fluid. Adequate hydration should be maintained for all patients. In the event of acute renal failure and anuria, the patient may benefit from hemodialysis until renal function is restored [see Dosage and Administration (2.4), Adverse Reactions (6.3)]. 5.3 Central Nervous System Effects. Central nervous system adverse reactions, including agitation, hallucinations, confusion, delirium, seizures, and encephalopathy, have been reported in both adult and pediatric patients with or without reduced renal function and in patients with underlying renal disease who received higher than recommended doses of valacyclovir hydrochloride for their level of renal function. Elderly patients are more likely to have central nervous system adverse reactions. Valacyclovir hydrochloride should be discontinued if central nervous system adverse reactions occur [see Adverse Reactions (6.3), Use in Specific Populations (8.5, 8.6)].